288 related articles for article (PubMed ID: 36627024)
1. Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders.
Ramos P; Larson B; Ashrafzadeh-Kian S; Ito N; Kato H; Bornhorst JA; Algeciras-Schimnich A
Endocr Pract; 2023 Mar; 29(3):193-198. PubMed ID: 36627024
[TBL] [Abstract][Full Text] [Related]
2. Plasma intact fibroblast growth factor 23 level is a useful tool for diagnostic approach of renal hypophosphatemia.
Giralt M; Chocron S; Ferrer R; Ariceta G
Pediatr Nephrol; 2021 Apr; 36(4):1025-1028. PubMed ID: 33492457
[TBL] [Abstract][Full Text] [Related]
3. Determination of FGF23 Levels for the Diagnosis of FGF23-Mediated Hypophosphatemia.
Hartley IR; Gafni RI; Roszko KL; Brown SM; de Castro LF; Saikali A; Ferreira CR; Gahl WA; Pacak K; Blau JE; Boyce AM; Salusky IB; Collins MT; Florenzano P
J Bone Miner Res; 2022 Nov; 37(11):2174-2185. PubMed ID: 36093861
[TBL] [Abstract][Full Text] [Related]
4. High iFGF23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH.
Igaki JM; Yamada M; Yamazaki Y; Koto S; Izawa M; Ariyasu D; Suzuki E; Hasegawa H; Hasegawa Y
Endocr J; 2011; 58(8):647-55. PubMed ID: 21597229
[TBL] [Abstract][Full Text] [Related]
5. Phosphatonins: From Discovery to Therapeutics.
Kritmetapak K; Kumar R
Endocr Pract; 2023 Jan; 29(1):69-79. PubMed ID: 36210014
[TBL] [Abstract][Full Text] [Related]
6. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
Kinoshita Y; Fukumoto S
Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
[TBL] [Abstract][Full Text] [Related]
7. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
[TBL] [Abstract][Full Text] [Related]
8. Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23.
Ito N; Kubota T; Kitanaka S; Fujiwara I; Adachi M; Takeuchi Y; Yamagami H; Kimura T; Shinoda T; Minagawa M; Okazaki R; Ozono K; Seino Y; Fukumoto S
J Bone Miner Metab; 2021 Nov; 39(6):1066-1075. PubMed ID: 34255195
[TBL] [Abstract][Full Text] [Related]
9. Iron and fibroblast growth factor 23 in X-linked hypophosphatemia.
Imel EA; Gray AK; Padgett LR; Econs MJ
Bone; 2014 Mar; 60():87-92. PubMed ID: 24325979
[TBL] [Abstract][Full Text] [Related]
10. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
Weber TJ; Liu S; Indridason OS; Quarles LD
J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
[TBL] [Abstract][Full Text] [Related]
11. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.
Imel EA; DiMeglio LA; Hui SL; Carpenter TO; Econs MJ
J Clin Endocrinol Metab; 2010 Apr; 95(4):1846-50. PubMed ID: 20157195
[TBL] [Abstract][Full Text] [Related]
12. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
Athonvarangkul D; Insogna KL
Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
[TBL] [Abstract][Full Text] [Related]
13. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment.
Endo I; Fukumoto S; Ozono K; Namba N; Inoue D; Okazaki R; Yamauchi M; Sugimoto T; Minagawa M; Michigami T; Nagai M; Matsumoto T
Endocr J; 2015; 62(9):811-6. PubMed ID: 26135520
[TBL] [Abstract][Full Text] [Related]
14. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
Fukumoto S
J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of PHEX Mutations and FGF23 Profiles in a Taiwanese Cohort With X-Linked Hypophosphatemia Including 102 Patients.
Su PH; Yu JS; Wu YZ; Tsai YS; Lo FS; Lin JL; Chao MC; Hsu CC; Ke YY; Chiu PC; Chen JC; Huang YH; Lin SP; Chou YY; Ting WH; Wang SY; Chiu CF; Huang YC; Hsiao HP; Lin CH; Wang CH; Bau DT; Lin CY
In Vivo; 2024; 38(1):341-350. PubMed ID: 38148081
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders.
Takashi Y; Kawanami D; Fukumoto S
Curr Opin Endocrinol Diabetes Obes; 2024 Aug; 31(4):170-175. PubMed ID: 38687287
[TBL] [Abstract][Full Text] [Related]
17. Tubular phosphate transport: a comparison between different methods of urine sample collection in FGF23-dependent hypophosphatemic syndromes.
Arcidiacono GP; Camozzi V; Zaninotto M; Tripepi G; Fusaro M; Torres MO; Zanchetta F; Cannito M; Cecchinato A; Diogo M; Peleg Falb M; Plebani M; Simioni P; Sella S; Giannini S
Clin Chem Lab Med; 2024 May; 62(6):1126-1132. PubMed ID: 38295343
[TBL] [Abstract][Full Text] [Related]
18. FGF23 and Associated Disorders of Phosphate Wasting.
Gohil A; Imel EA
Pediatr Endocrinol Rev; 2019 Sep; 17(1):17-34. PubMed ID: 31599133
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries.
Al Juraibah F; Al Amiri E; Al Dubayee M; Al Jubeh J; Al Kandari H; Al Sagheir A; Al Shaikh A; Beshyah SA; Deeb A; Habeb A; Mustafa M; Zidan H; Mughal MZ
Arch Osteoporos; 2021 Mar; 16(1):52. PubMed ID: 33660084
[TBL] [Abstract][Full Text] [Related]
20. Successful Burosumab Treatment in an Adult Patient with X-Linked Hypophosphatemia and Chronic Kidney Disease Stage 3b.
Michon-Colin A; Bouderlique E; Prié D; Maruani G; Nevoux J; Briot K; Courbebaisse M
Calcif Tissue Int; 2024 Mar; 114(3):310-314. PubMed ID: 38195892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
